The TenCRAO trial presented at the 22nd Euretina Congress in Hamburg

Romozzi M, Iannone LF, Russo A, Finkelstein I, Seabi D, Ahlden A, Aamodt AH, Vollono C, Calabresi P, Caronna E, Pozo-Rosich P, Tronvik EA, Sundal C (2026)
Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort)
Neurol Ther (in press)
DOI 10.1007/s40120-026-01045-4, PubMed 42839214

Helland GB, Enriquez B, Beyer MK, Rise HS, Ihle-Hansen H, Andersson S, Grambaite R, Stangeland H, Vaskinn A, Ihle-Hansen H, Harbo HF, Høgestøl EA, Hagberg G, Aamodt AH (2026)
Response to "letter to the editor" by Zhang and Liu, concerning "long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study"
J Neurol Sci, 490, 126138
DOI 10.1016/j.jns.2026.126138, PubMed 42636687

Helland GB, Enriquez B, Beyer MK, Rise HS, Ihle-Hansen H, Andersson S, Grambaite R, Stangeland H, Vaskinn A, Ihle-Hansen H, Harbo HF, Høgestøl EA, Hagberg G, Aamodt AH (2026)
Long-term social cognitive impairment after ischemic stroke: Frequency and association with lesion volume and location in an exploratory pilot study
J Neurol Sci, 489, 126075
DOI 10.1016/j.jns.2026.126075, PubMed 42391747